News
Poietis signs agreement with Prometheus to bio-print cartilage
French bio-printing specialist, Poietis, has announced a new research agreement with Prometheus, the tissue engineering department of KU Leuven in Belgium. Their goal is to develop bio-printing of advanced therapy drugs in cartilage regeneration. For two years, both actors will&h
- 3 min read
- News
- Six more stories

French bio-printing specialist, Poietis, has announced a new research agreement with Prometheus, the tissue engineering department of KU Leuven in Belgium. Their goal is to develop bio-printing of advanced therapy drugs in cartilage regeneration. For two years, both actors will be working in the field of tissue engineering to create cartilage cells.
Tissue engineering enables researchers to understand the different functions and structures of both normal and pathological tissues. Through this, they are then able to find biological substitutes that can restore, maintain or improve the functions of these tissues. In 2014, this market was worth $4.7 billion and is expected to reach $11.5 billion in 2022. The development of different bio-printing technologies is a major contributor to this growth as it allows for the creation of complex cellular structures more quickly, efficiently and cheaper.

One of Poietis’ bio-printers
Bio-printing for tissue engineering
By signing this research agreement with Prometheus, Poietis will benefit from their expertise in tissue engineering and more specifically in osteocartilaginous regeneration. The Belgian platform is specialized in the development of innovative therapy drugs where medical needs are not met. The French company is expanding all of its partners, such as their recent agreement signing with BASF to bio-print skin and L’Oréal to reproduce hair follicles.





